Autoimmune Hepatitis Clinical Trials

Find Autoimmune Hepatitis Clinical Trials Near You

A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis

Status: Recruiting
Location: See all (20) locations...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The main objectives of this trial are to evaluate the safety and tolerability of inebilizumab in participants with autoimmune hepatitis (AIH) (Part 1) and to evaluate the efficacy of inebilizumab on AIH disease activity and glucocorticoid (GC) use in the management of AIH (Part 2).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 74
Healthy Volunteers: f
View:

• Signed informed consent.

• Age ≥ 18 years or legal adult age within the country, whichever is older and \< 75 years at the time of signing the informed consent.

• Participants must have either inadequate response to at least 9 months of SOC or are intolerant to SOC within 6 months of screening. Inadequate response to SOC treatment is defined as ALT ≥ 2 upper limit of normal (ULN) at screening after at least 9 months of SOC, including prednisone (or equivalent) \> 5 mg/day and at least one conventional steroid sparing agent at guideline-concordant target or highest appropriate dose, that is azathioprine (AZA) or 6-mercaptopurine (6-MP) at appropriate weight-based dosing (typically up to 2 mg/kg/day AZA or 1 mg/kg/day 6-MP) or mycophenolate (MMF) up to 2 g/day, as judged appropriate by the investigator and documented in the medical record.

∙ Intolerance to SOC treatment is defined as any clinically significant adverse event related to treatment that results in discontinuation of the medication or prevents dose optimization necessary to achieve or maintain biochemical response, as determined by the Principal Investigator (PI). Intolerance applies to GCs, AZA, 6-MP, or MMF. Presence of one or more clinically significant adverse effects attributed to SOC include but not limited to side effects that, in the opinion of the investigator, compromise participant's safety or quality of life, exacerbate comorbid conditions, or render continued use medically inappropriate.

• Participants with disease activity at screening as follows: ALT ≥ 2 x ULN to ≤ 7 x ULN. ALT ULN values will be gender specific.

• Participant must have a biopsy proven definitive diagnosis of AIH according to simplified diagnostic criteria (score ≥ 7). Liver biopsy should be obtained within 90 days prior to randomization. Participants must have a mHAI score ≥ 5 in the biopsy.

• Participant should be on:

‣ No increase in GC dose during the 28 days immediately preceding whichever biopsy is designated as the baseline sample-historical or screening-and the dose post biopsy must remain unchanged through the day of randomization AND

⁃ Stable maximum tolerated doses of AZA or 6-MP for at least 12 weeks prior to screening (baseline) liver biopsy until randomization and during the entire treatment period unless dose reduction is deemed necessary for safety or tolerance reasons OR

⁃ Stable maximum tolerated doses of MMF/mycophenolic acid (MPA) for at least 12 weeks prior to screening (baseline) liver biopsy until randomization and during the entire treatment period unless dose reduction is deemed necessary for safety or tolerance reasons.

• Participants must use protocol-specified contraception during treatment and for an additional 6 months after the last dose of trial intervention.

Locations
United States
Arkansas
Applied Research Center of Arkansas
RECRUITING
Little Rock
California
Inland Empire Liver Foundation
RECRUITING
Rialto
Amicis Research Center
TERMINATED
Valencia
Florida
Floridian Clinical Research LLC
RECRUITING
Miami Lakes
Indiana
Indiana University
RECRUITING
Indianapolis
Texas
Methodist Cardiovascular Consultants - Dallas
RECRUITING
Dallas
American Research Corporation
RECRUITING
San Antonio
Other Locations
Canada
McGIll University Health Centre Glen Site
RECRUITING
Montreal
China
Beijing Friendship Hospital, Capital Medical University
RECRUITING
Beijing
Peking Union Medical College Hospital
RECRUITING
Beijing
Peking University First Hospital
RECRUITING
Beijing
The First Bethune Hospital of Jilin University
RECRUITING
Changchun
West China Hospital Sichuan University
RECRUITING
Chengdu
The Second Affiliated Hospital of Chongqing Medical University
RECRUITING
Chongqing
The Second Hospital of Anhui Medical University
RECRUITING
Hefei
The Second Hospital of Nanjing
RECRUITING
Nanjing
Renji Hospital Shanghai Jiaotong University School of Medicine
RECRUITING
Shanghai
The Fifth Peoples Hospital of Suzhou
RECRUITING
Suzhou
Union Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITING
Wuhan
The First Affiliated Hospital of Zhengzhou University
RECRUITING
Zhengzhou
Contact Information
Primary
Amgen Call Center
medinfo@amgen.com
866-572-6436
Time Frame
Start Date: 2026-10-13
Estimated Completion Date: 2034-02-11
Participants
Target number of participants: 180
Treatments
Experimental: Part 1: Inebilizumab
Participants will receive inebilizumab as an intravenous (IV) infusion in addition to standard of care (SOC).
Experimental: Part 1: Placebo
Participants will receive placebo as an IV infusion in addition to SOC.
Experimental: Part 2: Inebilizumab
Participants will receive Inebilizumab as an IV infusion in addition to SOC.
Experimental: Part 2: Placebo
Participants will receive placebo as an IV infusion in addition to SOC.
Related Therapeutic Areas
Sponsors
Leads: Amgen

This content was sourced from clinicaltrials.gov